Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbuhaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation powder for oral inhalation use. It provides bronchodilation for patients with asthma and chronic obstructive pulmonary disease (COPD). GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth muscle to improve airflow in obstructive lung diseases.

- Asthma: improves control of symptoms and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation and helps reduce breathlessness. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

Formoterol may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Tremor: mild shaking of the hands. - Headache: occasional mild to moderate headache. - Throat irritation: sensation of dryness or irritation in the throat. - Cough: transient cough after inhalation. - Palpitations: awareness of heartbeat that is usually benign. - Nasal congestion: mild blockage of the nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmias: irregular heart rhythms that may require medical attention. - Hypokalemia: low blood potassium levels. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose levels, particularly in diabetic patients. - Chest pain: unexplained chest discomfort that should be evaluated promptly.

When prescribing Oxis Turbuhaler, clinicians should consider several safety aspects.

- Assess respiratory status: evaluate baseline lung function before initiating therapy. - Monitor for cardiovascular effects: watch for tachycardia, palpitations, or blood pressure changes. - Review concomitant medications: avoid combining with other LABA‑only products. - Caution in pregnancy: limited data; use only if the potential benefit outweighs risk. - Educate on proper inhaler technique: ensure patients receive training to minimize local irritation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Formoterol may interact with several medications that affect cardiovascular or respiratory function.

Major Interactions (Avoid): - Beta‑beta   ");